9 recruiting, 4 terminated, 3 not yet recruiting, 1 active not recruiting. 15 Phase 2, 14 Phase 1, 1 Phase 3.
Follow LaNova Medicines Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors LM-364 for injection, Tislelizumab - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Not yet recruiting | LaNova Medicines Limited | 90 | 2026-10-19 | 2026-10-14 |
| A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors LM-168, Tislelizumab, Docetaxel injection - Advanced Solid Tumor | Phase 2 | Recruiting | LaNova Medicines Limited | 108 | 2026-07-29 | 2026-07-30 |
| A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors LM-364 for injection, Tislelizumab - Malignant Tumors | Phase 1 / Phase 2 | Not yet recruiting | LaNova Medicines Limited | 90 | 2026-07-15 | 2026-07-10 |
| LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma LM-108 in combination with Toripalimab, Paclitaxel injection intravenous infusion - Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Phase 3 | Recruiting | LaNova Medicines Limited | 400 | 2026-04-30 | 2026-05-11 |
| Phase II Study of LM-24C5 LM-24C5 - Advanced Solid Tumor Cancer | Phase 2 | Recruiting | LaNova Medicines Limited | 130 | 2025-12-15 | 2026-02-04 |
| A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours LM-2417, Docetaxel, Toripalimab/Tirelizumab - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 320 | 2025-09-17 | 2026-08-28 |
| A Study of LM-350 in Subjects With Advanced Solid Tumours LM-350 for injection - Malignant Tumors | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 80 | 2025-08-28 | 2026-01-26 |
| A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours LM-168, Toripalimab - Advanced Solid Tumours | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 87 | 2025-05-06 | 2025-09-12 |
| A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours LM-108, Toripalimab - Advanced Solid Tumor | Phase 2 | Not yet recruiting | LaNova Medicines Limited | 84 | 2025-03-26 | 2025-03-13 |
| Study of LM-299 in Subjects Advanced Malignant Tumors LM-299 - Malignant Tumors | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 108 | 2024-10-09 | 2025-05-02 |
| A Study of LM-24C5 For Advanced Solid Tumors LM-24C5 - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 49 | 2023-12-20 | 2025-09-09 |
| Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases LM-305, Dexamethasone - Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases | Phase 1 / Phase 2 | Withdrawn | LaNova Medicines Limited | 2023-01-18 | 2023-11-18 | |
| A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors LM101, Toripalimab, Rituximab - Malignant Tumors | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 139 | 2023-01-11 | 2024-12-19 |
| A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors LM-108, Toripalimab - Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | LaNova Medicines Limited | 392 | 2022-08-26 | 2026-09-03 |
| Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours LM-108, An Anti-PD-1 Antibody - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | LaNova Medicines Limited | 24 | 2022-05-26 | 2023-10-25 |
| Study of LM-102 in Subjects in Advanced Tumors Drugļ¼LM-102 - Advanced Solid Tumors | Phase 1 | Terminated | LaNova Medicines Limited | 9 | 2021-05-27 | 2022-10-26 |
| A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours LM-061 - Advanced Tumours | Phase 1 / Phase 2 | Terminated | LaNova Medicines Limited | 18 | 2021-05-20 | 2023-07-27 |
| Study of LM-061 in Subjects in Advanced Tumors LM-061, Toripalimab - Advanced Tumours | Phase 1 | Terminated | LaNova Medicines Limited | 18 | 2021-05-06 | 2023-10-10 |
Neoplasms (4) · Multiple Myeloma (1) · Recurrence (1)
toripalimab (7) · Injections (3) · tislelizumab (3) · Docetaxel (2) · Carboplatin (1) · Dexamethasone (1) · Rituximab (1) · lenvatinib (1) · niraparib (1)
China (12) · Australia (5) · United States (3)
Lin Shen (2) · Depei Wu (1) · Ganessan Kichenadasse (1) · Gary Richardson (1) · Paul De Souza (1) · Sherry Qin (1) · Terry Pang (1) · Vinod Ganju (1)